BP MedTech Participating Institutes/Centers and Programs

The following Institutes, Centers, and Offices will be participating in the Blueprint MedTech program. Institute specific interests are also provided below. Interested applicants are encouraged to contact NIH Scientific/Research staff for more information about this program before submitting an application.

Brain Research Through Advancing Innovative Neurotechnologies® (BRAIN) Initiative
Contact: Theresa Cruz, Ph.D.Nick Langhals, Ph.D.
There is a need to help transition BRAIN Initiative-relevant technologies from early device development to first-in-human studies. Projects that fit the following categories can be submitted through the Blueprint MedTech Program. BRAIN will support the following efforts coming into the BP MedTech UG3/UH3 and U44 funding opportunities:

  • Projects developing novel invasive neurostimulation devices for the human central nervous system (CNS).
  • Projects developing novel invasive brain recording devices for the human CNS.
  • Projects developing novel non-invasive brain stimulation devices for the human CNS. These devices should aim to achieve brain stimulation resolution of sub-millimeter at the cortical surface and depth. These approaches may incorporate electromagnetic, mechanical, or combination biological and device means (e.g., optogenetics).

For more information,  see the Notice of Shared Interest (NOSINOT-NS-22-052.

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Contact: Theresa Cruz, Ph.D.Antonello Pileggi, M.D., Ph.D.
The National Center for Medical Rehabilitation Research within NICHD supports assistive and rehabilitation technology to improve the function of people with physical disabilities.

Helping to End Addiction Long-term (HEAL) Initiative
Contact: Eric Hudak, Ph.D.

Through Notice of Special Interest (NOSI) NOT-NS-23-002, the NIH HEAL Initiative encourages the translation of novel neurotechnologies, funded through the Helping to End Addiction Long-Term (HEAL) Initiative and overseen by the NIH Blueprint MedTech program. There is a need to help transition HEAL Initiative-relevant technologies from early device development to first-in-human studies. HEAL will support projects developing novel invasive or non-invasive devices for the diagnosis and/or treatment of pain and/or OUD. More information about the HEAL Initiative is available at: https://heal.nih.gov/.

National Center for Complementary and Integrative Health (NCCIH) 
Contact: Emrin Horgusluoglu, Ph.D.
NCCIH supports the development and validation of innovative technology to advance fundamental understanding, enhance and monitor usage, or determine the usefulness and safety of a variety of complementary and integrative health approaches, including natural products and/or mind and body approaches, relevant to the nervous system. 

National Eye Institute (NEI)
Contact: Tony Gover, Ph.D.Paek Lee, Ph.D.
NEI is interested in the development of tools and/or novel therapies, devices, assistive devices and diagnostics for the treatment of visual system diseases and disorders.

National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Contact: Michael Wolfson, Ph.D.; Moria Bittmann, Ph.D.
The mission of NIBIB is to improve health by leading the development and accelerating the application of biomedical technologies. NIBIB has broad interests in the development of biomedical technologies to improve human health and address health disparities.

National Institute of Dental and Craniofacial Research (NIDCR)
Contact: Melissa Ghim, Ph.D.; Margaret Grisius, D.D.S.Lorena Baccaglini, D.D.S., Ph.D.
NIDCR is interested in:

  • Development of technologies for oral somatosensory stimulation to enable diagnosis and treatment of motor and sensory conditions, such as bruxism, sleep apnea, temporomandibular/facial pain, swallowing reflex, and other dental, oral, and craniofacial related neuromuscular conditions and disorders. These technologies can include the integration of intra- and extra-oral sensors and relevant treatment delivery mechanisms controlled by software systems that allow capture, analysis and display of target biosignatures including but not limited to neural activity. 
  • Biofeedback & multimodal neurofeedback technologies for treatment of facial nerve disorders, as well as neurological (e.g., trigeminal neuralgia, peripheral neuropathy associated with Sjogren’s syndrome, burning mouth syndrome) and non-neurological (e.g., vascular/muscular, immune) facial pain. These technologies can include wearable and embeddable devices to address acute and chronic conditions

National Institute of Mental Health (NIMH)
Contact: John Greene, Ph.D. (interim); Margaret (Meg) Grabb, Ph.D.Jessica Tilghman, Ph.D. (on leave)
NIMH is specifically interested in novel brain stimulation/modulation technologies (invasive or noninvasive) for use in the treatment of psychiatric disorders, or in targeting specific domains of clinical functioning across psychiatric disorders, when appropriate (see RDOC). Devices capable of both recording and stimulating neural activity, with the ability for closed-loop control are also of interest (including synchronizing dense behavioral quantification with neural data); these devices should be able to demonstrate clear capability to record oscillations of interest to mental health applications. Devices can target specific age ranges, including vulnerable populations (pediatric, geriatric). Note:  Animal studies to assess “efficacy” must follow NIMH criteria.  Please contact NIMH staff above to ensure your project fits NIMH priorities, prior to application submission.

Office of Behavioral and Social Sciences Research (OBSSR)
Contact: Dana Greene (formerly Schloesser), Ph.D.

National Institute of Neurological Disorders and Stroke (NINDS)   
Contact: Nick Langhals, Ph.D.Emily Caporello, Ph.D.
NINDS will support translational device applications relevant to its mission.

National Institute on Aging (NIA)  
Contact: Kristina McLinden, Ph.D.Yuan Luo, Ph.D.
The mission of NIA is to improve the health and well-being of older adults through research. NIA is at the forefront of scientific discovery about the nature of healthy aging, and of research in prevention/therapeutics for Alzheimer’s disease (AD) and related dementias (ADRD). NIA highly supports the development and application of innovative technology for early diagnosis and treatment of age-related sensory and motor disorders and AD/ADRD.

National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Contact: Elizabeth Powell, Ph.D.
NIAAA supports basic, translational, and clinical research on the causes, consequences, prevention, diagnosis, progression, and treatment of alcohol-related problems across the lifespan. NIAAA also encourages meritorious research projects on alcohol-related topics of relevance to understanding and addressing minority health and health disparities.

National Institute on Drug Abuse (NIDA)
Contact: Leonardo Angelone, Ph.D.Stacie Gutowski, Ph.D.; Dan Kostov, Ph.D. 
NIDA will support applications aiming to develop novel medical devices intended for use in the diagnosis of, or in the cure, mitigation, treatment, or prevention of Substance Use Disorder (e.g., Opioid Use Disorder, Stimulant Use Disorder). See the NIDA Mission for additional details.

Common Date Element Usage
Please note that many Blueprint ICs expect or strongly encourage the collection of Common Data Elements (CDEs) for the research supported by their IC. Applicants to BP MedTech FOAs are encouraged to contact the POC for relevant ICs for more information on IC-specific data sharing expectations and requirements.